Good play on a speculative migraine pain management device. Around 600 M shares outstanding with low float and virtually no debt.
A small investment in ADHC could yield exponential returns in a few short years. Market cap could exceed to over 11B+ with successful FDA and clinical studies then successful marketplace execution.
Over $1 PPS is not unreasonable with this massive pain management market.